QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

MIRM

QT53Mirum Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
107.13
+5.09+4.99%
OverviewShort InterestFilings
MIRMQT53Mirum Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
107.13+4.99%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)-13.62
Insider Own43.54%
Shs Outstand60.98M
Perf Week7.63%
Market Cap5.12BForward P/E-EPS next Y-0.67Insider Trans0.96%Shs Float-Perf Month12.00%
Enterprise Value5.12BPEG0.00EPS next Q-0.74Inst Own-Short Float-Perf Quarter18.09%
Income-681260653.00P/S8.99EPS this Y-14.91%Inst Trans-Short Ratio-Perf Half Y59.78%
Sales569.61MP/B24.76EPS next Y95.73%ROA-89.67%Short Interest-Perf YTD35.62%
Book/sh3.97P/C-EPS next 5Y-ROE-289.33%52W High115.00 -6.84%Perf Year111.30%
Cash/sh6.33P/FCF-EPS past 3/5Y-ROIC-11.30%52W Low47.89 123.70%Perf 3Y-
Dividend Est.-EV/EBITDA-6.73Sales past 3/5Y89.14% -Gross Margin81.36%Volatility2.72% 3.08%Perf 5Y-
Dividend TTM-EV/Sales8.99EPS Y/Y TTM-635.68%Oper. Margin-12.31%ATR (14)4.69Perf 10Y-
Dividend Ex-Date-Quick Ratio1.99Sales Y/Y TTM69.14%Profit Margin-140.24%RSI (14)64.65Recom1.86
Dividend Gr. 3/5Y-Current Ratio2.09EPS Q/Q-4376.67%SMA209.51%Beta1.10Target Price144.91
Payout0.00%Debt/Eq1.34Sales Q/Q42.86%SMA508.62%Rel Volume1.67Prev Close102.04
Employees334LT Debt/Eq1.01EarningsJul 30SMA20024.34%Avg Volume944.52KPrice107.13
IPO DateJul 18, 2019Option/ShortYes / YesEPS/Sales Surpr.-3257.50% 8.11%Net Debt/EBITDA0.00Volume1,576,815Change4.99%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-15-26ReiteratedCLSA$146
Jun-11-26ReiteratedMorgan StanleyOverweight$140 → $150
May-19-26InitiatedWolfe ResearchOutperform$145
May-07-26ReiteratedRaymond JamesStrong Buy$164 → $165
May-07-26ReiteratedH.C. Wainwright$175 → $185
May-07-26ReiteratedEvercore ISI$135 → $138
May-07-26ReiteratedStifel Nicolaus$130 → $136
May-07-26ReiteratedRobert W. Baird$112 → $129
May-07-26ReiteratedRBC CapitalOutperform$128 → $142
May-05-26ReiteratedMorgan StanleyOverweight$95 → $140
Latest News
Jun-15-26
Jun-15-2610:06AM
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $146Benzinga
02:53AM
Reported Sunday, Mirum Pharmaceuticals And Incyte Report Pivotal Phase 2 PROGRESS Study Results For Zilurgisertib Showing 99.9% Reduction In New HO Lesion Volume In Fibrodysplasia Ossificans Progressiva Patients At Week 24Benzinga
Jun-11-26
Jun-11-2608:24AM
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $150Benzinga
08:24AM
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $150Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue570521337
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A10610182
Gross Profit463421255
Selling, General and Administrative Excl. Other295257202
Research and Development238186141
Other Operating Expense000
Operating Income-70-22-88
Interest Expense161414
Unusual Expense
———
Non-Operating Income (Expense)717-15-15
Net Income Before Taxes-797-21-87
Income Taxes121
Consolidated Net Income-799-23-88
Net Income From Continuing Operations-799-23-88
Net Income-799-23-88
EPS (Recurring)-13.61-0.47-1.85
EPS (Basic, Before Extraordinaries)-13.61-0.47-1.85
EPS (Diluted)-13.62-0.47-1.85
EBITDA-76117-49
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio11.097.58—
Gross Margin81.2380.8175.67
Operating Margin-12.28-4.22-26.11
Net Margin-140.18-4.41-26.11
Shares Outstanding595048
Market Capitalization6,3213,949—
Operating Lease Expense
———
Insider Trading Volume
$132.85$124.35$115.85$107.35$98.85● Close Price0.00M2.25M4.50M6.75M9.00MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BJERKHOLT ERICCHIEF FINANCIAL OFFICERJun 09 '26Option Exercise26.494,786126,78247,181Jun 09 12:00 AM
BJERKHOLT ERICCHIEF FINANCIAL OFFICERJun 08 '26Sale93.825,000469,07744,788Jun 09 12:00 AM
Radovich PeterPRESIDENT AND COOJun 05 '26Option Exercise19.1933,976652,00057,260Jun 08 12:00 AM
Peetz ChristopherCHIEF EXECUTIVE OFFICERJun 01 '26Sale95.8430,0002,875,103194,309Jun 02 12:00 AM
Ramasastry SairaDirectorJun 01 '26Sale100.003,977397,7000Jun 02 12:00 AM
Peetz ChristopherCHIEF EXECUTIVE OFFICERJun 01 '26Option Exercise2.9460,000176,160224,309Jun 02 12:00 AM
Walbert Timothy PDirectorMay 29 '26Option Exercise0.007,95409,680Jun 02 12:00 AM
Cardon LonDirectorMay 29 '26Option Exercise0.007,95409,680Jun 02 12:00 AM
Ramasastry SairaDirectorMay 29 '26Option Exercise0.007,95403,977Jun 02 12:00 AM
Fischer LaurentDirectorMay 29 '26Option Exercise0.007,954010,727Jun 02 12:00 AM
Ramasastry SairaDirectorMay 15 '26Option Exercise23.514,00094,0402,000May 18 12:00 AM
Ramasastry SairaDirectorMay 15 '26Sale109.472,000218,9400May 18 12:00 AM
Ramasastry SairaDirectorApr 15 '26Option Exercise23.514,00094,0402,000Apr 16 12:00 AM
Ramasastry SairaDirectorApr 15 '26Sale96.902,000193,8000Apr 16 12:00 AM
Ramasastry SairaDirectorMar 16 '26Sale90.762,000181,5200Mar 17 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR